Back

Effects of CYP3A4*22 carrier and CYP3A5 expressor status on clinical outcome in patients treated with ticagrelor for acute coronary syndrome

28 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Coronary artery disease - Pharmacotherapy 2 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Jaouad Azzahhafi

St Antonius Hospital, Nieuwegein (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
P2Y12 inhibitors monotherapy in patients undergoing complex vs. non-complex percutaneous coronary intervention: a meta-analysis of randomized trials
Doctor A. Oliva (New York, US)
Abstract Slides
Presentation thumbnail
Liposomal docosahexaenoic acid halts atherosclerosis progression
Miss S. Chong (Singapore, SG)
Abstract Slides
Presentation thumbnail
The effect of vitamin k2 supplementation on coronary artery disease in a randomized multicenter trial
Doctor S. Hasific (Odense, DK)
Abstract Slides
Presentation thumbnail
Comparison of the Efficacy and Safety between different Oral P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome: a Systematic Review and Meta-Analysis
Doctor A. Lepone (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Coronary artery disease - Pharmacotherapy 2

The Event

Event poster

ESC Congress 2022

28 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources